Business Wire

Digi International Launches Digi WAN Bonding, Delivering Bonded Gigabit Internet Speeds and Improved Connection Reliability

Share

Digi International (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, today announced the release of its latest value-added service — Digi WAN Bonding — to deliver true Gigabit speeds for dramatically enhanced network performance. This solution, which is fully integrated into the Digi technology stack, also dramatically improves Internet reliability and increases bandwidth for customers in the enterprise, industrial and transportation sectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418006030/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Digi International Launches Digi WAN Bonding, Delivering Bonded Gigabit Internet Speeds and Improved Connection Reliability (Graphic: Business Wire)

Available as an add-on value-added service to the industry-leading IoT device and network management platform, Digi Remote Manager® (Digi RM), Digi WAN Bonding leverages the edge intelligence of Digi Accelerated Linux (DAL) OS, Digi’s powerful Linux-based operating system. Digi WAN Bonding enables customers running DAL OS on their Digi devices to centrally configure, deploy, and manage the bonding together of multiple WAN connections. This WAN aggregation provides a sophisticated blend of increased throughput speeds, WAN smoothing, packet redundancy, and seamless failover for always-on Internet connectivity.

Digi WAN Bonding yields four key benefits:

  • Increased bandwidth: By combining multiple connections, WAN bonding can provide a higher total bandwidth than any single connection for video streaming or file sharing.
  • Increased speed: Additionally, combining multiple WAN links supports increased speed for one or multiple devices, up to 1 Gbps maximum.
  • Improved reliability: WAN bonding also improves the reliability of your bonded communication channels. If a connection fails, the others continue to provide service.
  • Reduced costs: WAN bonding can also reduce costs, for example enabling enterprises to obtain lower monthly rates for multiple connections.

Improved network performance is of extreme benefit to organizations requiring excellent speed and resiliency for data-intensive applications. These include video streaming to multiple media displays, vehicle cameras, and video conferencing. By providing customers with hot failover protection, this service ensures that if one WAN connection fails, the other connection takes over, thereby minimizing network downtime. Digi WAN Bonding also allows companies to take advantage of multiple ISPs, which can result in cost savings when businesses can negotiate better pricing and/or secure a provider that offers the best value for their specific needs.

“Organizations the world over are constantly searching for ways to boost network speed and reliability,” said Kinana Hussain, Vice President of Product Management for Digi International. “By fully integrating bandwidth bonding technology with Digi’s DAL OS and Digi Remote Manager, we’re able to provide businesses that rely on their network for critical operations with ultra-fast, ultra-reliable network performance and cost-efficient connectivity they very much want and need.”

Digi WAN Bonding — developed in collaboration with Bondix Intelligence — is distinct in that it allows for a maximum throughput speed of up to one Gigabit per second, compared to max speeds of 200 Mbps from other WAN bonding services.

“At Bondix, we’ve been thrilled to partner with Digi on rolling out our Bondix S.A.NE technology as an add-on service to Digi Remote Manager,” said Martin Santner, Director of Sales and Business Development for Bondix Intelligence. “This collaboration simplifies WAN aggregation, putting the mission-critical capabilities of WAN bonding into the hands of those who need it, enabling them to offer faster, better, more reliable connectivity when and where it matters.”

S.A.NE, which is short for Simple Aggregation of Networks, is proprietary software engineered by Bondix Technology to ensure reliable voice, video, and data transmission connectivity for mobile and stationary deployments alike.

For more information, visit https://www.digi.com/products/iot-software-services/digi-wan-bonding.

About Digi International

Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye